stakehigh
JF-Expert Member
- Aug 9, 2019
- 6,377
- 3,491
Chanjo ya VVU ambayo imekuwa ikisubiriwa kwa shauku sana ya Johnson & Johnson imeshindwa kuonesha uwezo wa kutosha katika jaribio lililohusisha zaidi ya wanawake 2,600 Kusini mwa Jangwa la Sahara.
Ingawa chanjo ilionekana kuwa salama, bila athari mbaya, ufanisi wake katika kuzuia maambukizo ya VVU ulizidi kidogo asilimia 25.
Katika taarifa, Paul Stoffels, Afisa wa Masuala ya Kisayansi wa J & J aliwashukuru wanawake walioshiriki pamoja na washirika wa kampuni hiyo.
"Wakati tumesikitishwa kwamba chanjo haikutoa kiwango cha kutosha cha kinga dhidi ya maambukizi ya VVU katika jaribio la Imbokodo, utafiti huo utatupa matokeo muhimu ya kisayansi katika harakati zinazoendelea za chanjo ya kuzuia VVU," alisema
======
HIV/Aids screening test during a past World Aids Day. PHOTO | FILE
Though the vaccine was found to be safe, with no serious side effects, its efficacy in preventing HIV infection was just over 25 percent.
As a result, the "Imbokodo" trial that began in 2017 will now be halted, and the participants, from Malawi, Mozambique, South Africa, Zambia and Zimbabwe will be told whether they received the vaccine or placebo.
But the company will continue a parallel trial involving men who have sex with men and transgender individuals that is taking place in the Americas and Europe, where vaccine composition differs and so do the prevalent HIV strains.
In a statement, Paul Stoffels, chief scientific officer of J&J thanked the women who participated and the company's partners.
"While we are disappointed that the vaccine candidate did not provide a sufficient level of protection against HIV infection in the Imbokodo trial, the study will give us important scientific findings in the ongoing pursuit for a vaccine to prevent HIV," he said.
"We must apply the knowledge learned from the Imbokodo trial and continue our efforts to find a vaccine that will be protective against HIV," added Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases which co-funded the study.
The J&J vaccine uses similar adenovirus technology to its Covid-19 vaccine, and was delivered with four vaccinations over a year.
A genetically modified cold virus delivers genetic cargo carrying instructions for the host to develop "mosaic immunogens" -- molecules capable of inducing an immune response to a wide variety of HIV strains.
The last two doses also contained proteins that are found on the HIV virus itself, as well as a substance called an "adjuvant" that is meant to further spur the immune system.
The trial was analysed two years after the women, who were aged 18-35, received their first dose.
Researchers found that 63 participants who received the placebo and 51 who received the vaccine became infected with HIV, meaning the efficacy was 25.2 percent.
The participants were offered pre-exposure prophylaxis medication (PrEP) to help prevent HIV infection during the clinical trial.
The women who acquired HIV infection were directed to medical care and offered antiretroviral treatment.
Source: AFP
Ingawa chanjo ilionekana kuwa salama, bila athari mbaya, ufanisi wake katika kuzuia maambukizo ya VVU ulizidi kidogo asilimia 25.
Katika taarifa, Paul Stoffels, Afisa wa Masuala ya Kisayansi wa J & J aliwashukuru wanawake walioshiriki pamoja na washirika wa kampuni hiyo.
"Wakati tumesikitishwa kwamba chanjo haikutoa kiwango cha kutosha cha kinga dhidi ya maambukizi ya VVU katika jaribio la Imbokodo, utafiti huo utatupa matokeo muhimu ya kisayansi katika harakati zinazoendelea za chanjo ya kuzuia VVU," alisema
======
Experimental HIV vaccine fails in Africa
WEDNESDAY SEPTEMBER 01 2021
HIV/Aids screening test during a past World Aids Day. PHOTO | FILE
Summary
- Researchers found that 63 participants who received the placebo and 51 who received the vaccine became infected with HIV, meaning the efficacy was 25.2 percent.
Though the vaccine was found to be safe, with no serious side effects, its efficacy in preventing HIV infection was just over 25 percent.
As a result, the "Imbokodo" trial that began in 2017 will now be halted, and the participants, from Malawi, Mozambique, South Africa, Zambia and Zimbabwe will be told whether they received the vaccine or placebo.
But the company will continue a parallel trial involving men who have sex with men and transgender individuals that is taking place in the Americas and Europe, where vaccine composition differs and so do the prevalent HIV strains.
In a statement, Paul Stoffels, chief scientific officer of J&J thanked the women who participated and the company's partners.
"While we are disappointed that the vaccine candidate did not provide a sufficient level of protection against HIV infection in the Imbokodo trial, the study will give us important scientific findings in the ongoing pursuit for a vaccine to prevent HIV," he said.
"We must apply the knowledge learned from the Imbokodo trial and continue our efforts to find a vaccine that will be protective against HIV," added Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases which co-funded the study.
The J&J vaccine uses similar adenovirus technology to its Covid-19 vaccine, and was delivered with four vaccinations over a year.
A genetically modified cold virus delivers genetic cargo carrying instructions for the host to develop "mosaic immunogens" -- molecules capable of inducing an immune response to a wide variety of HIV strains.
The last two doses also contained proteins that are found on the HIV virus itself, as well as a substance called an "adjuvant" that is meant to further spur the immune system.
The trial was analysed two years after the women, who were aged 18-35, received their first dose.
Researchers found that 63 participants who received the placebo and 51 who received the vaccine became infected with HIV, meaning the efficacy was 25.2 percent.
The participants were offered pre-exposure prophylaxis medication (PrEP) to help prevent HIV infection during the clinical trial.
The women who acquired HIV infection were directed to medical care and offered antiretroviral treatment.
Source: AFP
